Law Offices of Thomas J. Lamb

  • Free Case Evaluation
  • Mesothelioma & Asbestos Diseases
  • Legal Compensation
  • Asbestos Overview
  • Common Questions
  • About Our Firm

Treatment of Pleural Mesothelioma: ASCO Guideline Update

January 31, 2025 By Thomas Lamb

Since the initial [American Society of Clinical Oncologists (ASCO)] clinical practice guideline on the treatment of malignant pleural mesothelioma (PM) was published in 2018, considerable progress has been made which has changed not only the management but even the name of this disease. This guideline update focuses on four key areas: the role of … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma treatments, pleural mesothelioma

The presence of pleural effusion is an independent prognostic factor in patients with malignant pleural mesothelioma

January 6, 2025 By Thomas Lamb

Abstract:  Malignant pleural mesothelioma (MPM) is a rare form of thoracic malignancy with a poor prognosis. Pleural effusion (PE) occurs in the majority of patients with MPM; however, its impact on MPM outcomes remains controversial. We searched for eligible patients from the Surveillance, Epidemiology, and End Results (SEER) database, and … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma diagnosis, pleural effusions

FDA Approves Pembrolizumab Plus Chemo for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

September 18, 2024 By Thomas Lamb

The FDA has approved [ Keytruda (pembrolizumab) ] plus pemetrexed and platinum chemotherapy in the frontline treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. Data from the phase 2/3 KEYNOTE-483 study (NCT02784171) showed that [ Keytruda (pembrolizumab) ] plus chemotherapy (n = 222) significantly … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, Keytruda, malignant mesothelioma, malignant pleural mesothelioma (MPM), mesothelioma treatments, pembrolizumab, pemetrexed, pleural mesothelioma

Chemotherapy increases CDA expression and sensitizes malignant pleural mesothelioma cells to capecitabine treatment

September 5, 2024 By Thomas Lamb

Abstract:  The combination of cisplatin and pemetrexed remains the gold standard chemotherapy for malignant pleural mesothelioma (MPM), although resistance and poor response pose a significant challenge. Cytidine deaminase (CDA) is a key enzyme in the nucleotide salvage pathway and is involved in the adaptive stress response to chemotherapy. The … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: chemotherapy, cisplatin, malignant pleural mesothelioma (MPM), mesothelioma treatments, pemetrexed

Challenging the Norm: Occurrence of Synchronous Pleural and Peritoneal Mesothelioma in a Female Patient

August 20, 2024 By Thomas Lamb

Abstract:  Here, we present a unique case involving a female patient in her 40s with synchronous malignant pleural and peritoneal mesothelioma, despite lacking a history of asbestos exposure. The patient's initial symptoms included dyspnoea, chest pain, cough, fever, appetite loss, and weight loss over a month. Clinical evaluation led to the … [Read more...]

Filed Under: Case Reports, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, peritoneal mesothelioma

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study

July 16, 2024 By Thomas Lamb

Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with a very poor prognosis. Recently, immune checkpoint inhibition (ICI) has taken center stage in the currently ongoing revolution that is changing standard-of-care treatment for several malignancies, including MPM. As multiple arguments and accumulating lines of evidence are … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma treatments

Malignant Pleural Mesothelioma: Analysis of 70 Cases in the Last Decade

June 18, 2024 By Thomas Lamb

Malignant Pleural Mesothelioma (MPM) is an aggressive tumor linked to asbestos exposure, with a latency period of about 40 years before symptoms appear. Despite affecting a minority of exposed individuals, its risk escalates with prolonged exposure. Originating from mesothelial cells, [ Malignant Pleural Mesothelioma (MPM) ] affected 30,870 … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma

FDA Fast Tracks UV1, Ipilimumab, and Nivolumab in Malignant Mesothelioma

February 6, 2024 By Thomas Lamb

The FDA has granted a fast track designation to the combination of UV1 with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma. This regulatory decision is supported by findings from the phase 2 NIPU trial which is evaluating UV1 in patients with unresectable malignant pleural mesothelioma. … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: Ipilimumab, malignant pleural mesothelioma (MPM), meso, mesothelioma treatments, Nivolumab

Exhaled Breath May Predict Treatment Outcomes in Patients With Mesothelioma

September 20, 2023 By Thomas Lamb

The identification of volatile organic compounds (VOCs) in exhaled breath is a promising opportunity for noninvasive detection and prediction of treatment outcomes in patients with mesothelioma, according to data from a pilot study presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, held … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma diagnosis, mesothelioma treatments

Feladilimab by GSK for Malignant Pleural Mesothelioma: Likelihood of Approval

August 28, 2023 By Thomas Lamb

[Feladilimab] is under development [by the pharmaceutical company GSK] for the treatment of [malignant pleural mesothelioma], advanced solid tumors including non-small cell lung cancer, squamous non-small cell lung cancer, bladder cancer, cervical cancer, esophageal, urothelial cancer, clear renal cell carcinoma, head and neck cancer squamous cell … [Read more...]

Filed Under: Medicine, Mesothelioma Tagged With: malignant pleural mesothelioma (MPM), mesothelioma treatments, pleural mesothelioma

Next Page »

Do I Have A Possible Case?

If you have a possible asbestos disease or mesothelioma lawsuit, you can get a free, confidential, and no obligation case review from asbestos lawyer Tom Lamb.

Main Navigation Menu

  • Asbestos Information Overview
  • NC Asbestos Exposure Sites
  • Asbestos Cancers / Diseases
  • Legal Compensation
  • Free Case Evaluation
  • About Our Law Firm
  • Attorney Tom Lamb
  • Recent News & Reports
  • Frequently Asked Questions
  • Sitemap

Attorney Tom Lamb

TJL@LambLawOffice.com

Phone: 800-426-9535

Lumina Station, Suite 225
1908 Eastwood Road
Wilmington, North Carolina

Please know that you can use our Quick Contact Form to tell us about your case.

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Website

LambLawOffice.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.